Literature DB >> 22578805

Algorithm for Pompe disease newborn screening: results from the Taiwan screening program.

Shu-Chuan Chiang1, Wuh-Liang Hwu, Ni-Chung Lee, Li-Wen Hsu, Yin-Hsiu Chien.   

Abstract

BACKGROUND: Pompe disease is caused by a deficiency in acid α-glucosidase (GAA) and results in progressive, debilitating, and often life-threatening symptoms. Newborn screening has led to the early diagnosis of Pompe disease, but the best algorithm for screening has not yet been established.
MATERIALS AND METHODS: GAA and neutral α-glucosidase (NAG) activities in dried blood spots (DBSs) were assayed using 4-methylumbelliferyl-β-d-glucopyranoside as the substrate. We also measure α-galactosidase A (GLA) activity in DBSs for comparison. A total of 473,738 newborns were screened for Pompe disease, and the data were analyzed retrospectively to determine the best screening algorithm.
RESULTS: The fluorescence assay used in the screening possessed good reproducibility, but the NAG/GAA ratio was superior in separating the true-positive from the false-positive cases. An NAG/GAA cutoff ratio≥60 produces a positive predictive value (PPV) of 63.4%, and in our sample, only two cases of later-onset Pompe disease would have been missed. The GLA/GAA ratio is not as effective as the NAG/GAA ratio.
CONCLUSION: A suitable control enzyme can improve the performance of newborn screening. Newborn screening for Pompe disease can be performed using the NAG/GAA ratio as a cutoff even in the presence of GAA partial deficiency.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22578805     DOI: 10.1016/j.ymgme.2012.04.013

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  25 in total

1.  Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

Authors:  Na Lin; Jingyu Huang; Sara Violante; Joseph J Orsini; Michele Caggana; Erin E Hughes; Colleen Stevens; Lisa DiAntonio; Hsuan Chieh Liao; Xinying Hong; Farideh Ghomashchi; Arun Babu Kumar; Hui Zhou; Ruth Kornreich; Melissa Wasserstein; Michael H Gelb; Chunli Yu
Journal:  Clin Chem       Date:  2017-02-14       Impact factor: 8.327

Review 2.  Newborn screening: Taiwanese experience.

Authors:  Yin-Hsiu Chien; Wuh-Liang Hwu; Ni-Chung Lee
Journal:  Ann Transl Med       Date:  2019-07

Review 3.  Newborn Screening for Lysosomal Storage Disorders.

Authors:  Roy W A Peake; Olaf A Bodamer
Journal:  J Pediatr Genet       Date:  2016-12-02

Review 4.  Lysosomal diseases: diagnostic update.

Authors:  Bryan Winchester
Journal:  J Inherit Metab Dis       Date:  2014-04-08       Impact factor: 4.982

Review 5.  Newborn screening for lysosomal storage diseases.

Authors:  Michael H Gelb; C Ronald Scott; Frantisek Turecek
Journal:  Clin Chem       Date:  2014-12-04       Impact factor: 8.327

6.  Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe Disease.

Authors:  Hsuan-Chieh Liao; Min-Ju Chan; Chia-Feng Yang; Chuan-Chi Chiang; Dau-Ming Niu; Chun-Kai Huang; Michael H Gelb
Journal:  Clin Chem       Date:  2017-04-27       Impact factor: 8.327

Review 7.  Pompe disease: literature review and case series.

Authors:  Majed Dasouki; Omar Jawdat; Osama Almadhoun; Mamatha Pasnoor; April L McVey; Ahmad Abuzinadah; Laura Herbelin; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 8.  Lysosomal storage diseases.

Authors:  Carlos R Ferreira; William A Gahl
Journal:  Transl Sci Rare Dis       Date:  2017-05-25

9.  Enzymatic Screening and Diagnosis of Lysosomal Storage Diseases.

Authors:  Chunli Yu; Qin Sun; Hui Zhou
Journal:  N Am J Med Sci (Boston)       Date:  2013

10.  Newborn screening for hunter disease: a small-scale feasibility study.

Authors:  G J G Ruijter; D A Goudriaan; A M Boer; J Van den Bosch; A T Van der Ploeg; L H Elvers; S S Weinreich; A J Reuser
Journal:  JIMD Rep       Date:  2013-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.